메뉴 건너뛰기




Volumn 11, Issue 9, 2010, Pages 845-852

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: A phase 2 trial

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

EID: 77956189945     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70175-3     Document Type: Article
Times cited : (219)

References (40)
  • 2
    • 76049128595 scopus 로고    scopus 로고
    • Estimates of cancer incidence and mortality in Europe in 2008
    • Ferlay J, Parkin DM, Steliarova-Foucher E Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781.
    • (2010) Eur J Cancer , vol.46 , pp. 765-781
    • Ferlay, J.1    Parkin, D.M.2    Steliarova-Foucher, E.3
  • 3
    • 47249124557 scopus 로고    scopus 로고
    • First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?
    • Loupakis F, Masi G, Vasile E, Falcone A First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?. Curr Opin Oncol 2008, 20:459-465.
    • (2008) Curr Opin Oncol , vol.20 , pp. 459-465
    • Loupakis, F.1    Masi, G.2    Vasile, E.3    Falcone, A.4
  • 4
    • 68949094312 scopus 로고    scopus 로고
    • Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy
    • Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009, 27:3677-3683.
    • (2009) J Clin Oncol , vol.27 , pp. 3677-3683
    • Kopetz, S.1    Chang, G.J.2    Overman, M.J.3
  • 5
    • 55049130752 scopus 로고    scopus 로고
    • Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials
    • O'Neil BH, Goldberg RM Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. Oncologist 2008, 13:1074-1083.
    • (2008) Oncologist , vol.13 , pp. 1074-1083
    • O'Neil, B.H.1    Goldberg, R.M.2
  • 6
    • 0034729931 scopus 로고    scopus 로고
    • Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis
    • for the Meta-Analysis Group in Cancer
    • Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet 2000, 356:373-378. for the Meta-Analysis Group in Cancer.
    • (2000) Lancet , vol.356 , pp. 373-378
    • Buyse, M.1    Thirion, P.2    Carlson, R.W.3    Burzykowski, T.4    Molenberghs, G.5    Piedbois, P.6
  • 7
    • 33747844588 scopus 로고    scopus 로고
    • Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis
    • Johnson KR, Ringland C, Stokes BJ, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 2006, 7:741-746.
    • (2006) Lancet Oncol , vol.7 , pp. 741-746
    • Johnson, K.R.1    Ringland, C.2    Stokes, B.J.3
  • 8
    • 23844448040 scopus 로고    scopus 로고
    • Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates
    • Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005, 16:1311-1319.
    • (2005) Ann Oncol , vol.16 , pp. 1311-1319
    • Folprecht, G.1    Grothey, A.2    Alberts, S.3    Raab, H.R.4    Kohne, C.H.5
  • 9
    • 2142703727 scopus 로고    scopus 로고
    • Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
    • Grothey A, Sargent D, Goldberg RM, Schmoll HJ Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004, 22:1209-1214.
    • (2004) J Clin Oncol , vol.22 , pp. 1209-1214
    • Grothey, A.1    Sargent, D.2    Goldberg, R.M.3    Schmoll, H.J.4
  • 10
    • 0036787717 scopus 로고    scopus 로고
    • Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer
    • Falcone A, Masi G, Allegrini G, et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002, 20:4006-4014.
    • (2002) J Clin Oncol , vol.20 , pp. 4006-4014
    • Falcone, A.1    Masi, G.2    Allegrini, G.3
  • 11
    • 19944425122 scopus 로고    scopus 로고
    • First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule
    • Masi G, Allegrini G, Cupini S, et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol 2004, 15:1766-1772.
    • (2004) Ann Oncol , vol.15 , pp. 1766-1772
    • Masi, G.1    Allegrini, G.2    Cupini, S.3
  • 12
    • 34249000361 scopus 로고    scopus 로고
    • Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest
    • Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007, 25:1670-1676.
    • (2007) J Clin Oncol , vol.25 , pp. 1670-1676
    • Falcone, A.1    Ricci, S.2    Brunetti, I.3
  • 13
    • 77956191560 scopus 로고    scopus 로고
    • FOLFOXIRI (irinotecan, oxaliplatin, infusional 5FU/LV) vs FOLFIRI as first-line treatment of metastatic colorectal cancer (mCRC): updated results after 5 years follow up and risk-stratified analysis
    • (abstr).
    • Falcone A, Masi G, Vasile E, et al. FOLFOXIRI (irinotecan, oxaliplatin, infusional 5FU/LV) vs FOLFIRI as first-line treatment of metastatic colorectal cancer (mCRC): updated results after 5 years follow up and risk-stratified analysis. Ann Oncol 2009, 20(suppl 8):P-6085. (abstr).
    • (2009) Ann Oncol , vol.20 , Issue.SUPPL. 8
    • Falcone, A.1    Masi, G.2    Vasile, E.3
  • 14
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3
  • 15
    • 42949149159 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
    • Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
    • (2008) J Clin Oncol , vol.26 , pp. 2013-2019
    • Saltz, L.B.1    Clarke, S.2    Diaz-Rubio, E.3
  • 16
    • 34248173883 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
    • Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25:1539-1544.
    • (2007) J Clin Oncol , vol.25 , pp. 1539-1544
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3
  • 17
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauser EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauser, E.A.3
  • 18
    • 27244450852 scopus 로고    scopus 로고
    • OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer
    • Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 2005, 23:7125-7134.
    • (2005) J Clin Oncol , vol.23 , pp. 7125-7134
    • Poston, G.J.1    Adam, R.2    Alberts, S.3
  • 19
    • 63849088630 scopus 로고    scopus 로고
    • Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
    • Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
    • (2009) N Engl J Med , vol.360 , pp. 1408-1417
    • Van Cutsem, E.1    Kohne, C.H.2    Hitre, E.3
  • 20
    • 42649145667 scopus 로고    scopus 로고
    • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    • Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
    • (2008) J Clin Oncol , vol.26 , pp. 1626-1634
    • Amado, R.G.1    Wolf, M.2    Peeters, M.3
  • 21
    • 54949085398 scopus 로고    scopus 로고
    • K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    • Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
    • (2008) N Engl J Med , vol.359 , pp. 1757-1765
    • Karapetis, C.S.1    Khambata-Ford, S.2    Jonker, D.J.3
  • 22
    • 57449095367 scopus 로고    scopus 로고
    • Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
    • Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5705-5712.
    • (2008) J Clin Oncol , vol.26 , pp. 5705-5712
    • Di Nicolantonio, F.1    Martini, M.2    Molinari, F.3
  • 23
    • 68749119351 scopus 로고    scopus 로고
    • KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
    • Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009, 101:715-721.
    • (2009) Br J Cancer , vol.101 , pp. 715-721
    • Loupakis, F.1    Ruzzo, A.2    Cremolini, C.3
  • 24
    • 68149165771 scopus 로고    scopus 로고
    • Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
    • Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009, 101:465-472.
    • (2009) Br J Cancer , vol.101 , pp. 465-472
    • Souglakos, J.1    Philips, J.2    Wang, R.3
  • 25
    • 0033990048 scopus 로고    scopus 로고
    • Primer3 on the WWW for general users and for biologist programmers
    • Rozen S, Skaletsky H Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000, 132:365-386.
    • (2000) Methods Mol Biol , vol.132 , pp. 365-386
    • Rozen, S.1    Skaletsky, H.2
  • 26
    • 0020108590 scopus 로고
    • One-sample multiple testing procedure for phase II clinical trials
    • Fleming TR One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982, 38:143-151.
    • (1982) Biometrics , vol.38 , pp. 143-151
    • Fleming, T.R.1
  • 27
    • 39149108869 scopus 로고    scopus 로고
    • Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study
    • Fuchs CS, Marshall J, Barrueco J Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008, 26:689-690.
    • (2008) J Clin Oncol , vol.26 , pp. 689-690
    • Fuchs, C.S.1    Marshall, J.2    Barrueco, J.3
  • 28
    • 36048960109 scopus 로고    scopus 로고
    • Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study
    • Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007, 25:4779-4786.
    • (2007) J Clin Oncol , vol.25 , pp. 4779-4786
    • Fuchs, C.S.1    Marshall, J.2    Mitchell, E.3
  • 29
    • 67650996205 scopus 로고    scopus 로고
    • Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer
    • Sobrero A, Ackland S, Clarke S, et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 2009, 77:113-119.
    • (2009) Oncology , vol.77 , pp. 113-119
    • Sobrero, A.1    Ackland, S.2    Clarke, S.3
  • 30
    • 66149120036 scopus 로고    scopus 로고
    • Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
    • Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009, 20:1842-1847.
    • (2009) Ann Oncol , vol.20 , pp. 1842-1847
    • Van Cutsem, E.1    Rivera, F.2    Berry, S.3
  • 31
    • 70349413045 scopus 로고    scopus 로고
    • Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study
    • Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009, 14:862-870.
    • (2009) Oncologist , vol.14 , pp. 862-870
    • Kozloff, M.1    Yood, M.U.2    Berlin, J.3
  • 32
    • 63449116518 scopus 로고    scopus 로고
    • Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases
    • Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009, 249:420-425.
    • (2009) Ann Surg , vol.249 , pp. 420-425
    • Masi, G.1    Loupakis, F.2    Pollina, L.3
  • 33
    • 43249130975 scopus 로고    scopus 로고
    • Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality?
    • Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality?. J Clin Oncol 2008, 26:1635-1641.
    • (2008) J Clin Oncol , vol.26 , pp. 1635-1641
    • Adam, R.1    Wicherts, D.A.2    de Haas, R.J.3
  • 34
    • 56749096759 scopus 로고    scopus 로고
    • Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases
    • Blazer DG, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008, 26:5344-5351.
    • (2008) J Clin Oncol , vol.26 , pp. 5344-5351
    • Blazer, D.G.1    Kishi, Y.2    Maru, D.M.3
  • 35
    • 21244450758 scopus 로고    scopus 로고
    • Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab
    • Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005, 97:981-989.
    • (2005) J Natl Cancer Inst , vol.97 , pp. 981-989
    • Ince, W.L.1    Jubb, A.M.2    Holden, S.N.3
  • 36
    • 61449202998 scopus 로고    scopus 로고
    • The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer
    • Hurwitz HI, Yi J, Ince W, et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009, 14:22-28.
    • (2009) Oncologist , vol.14 , pp. 22-28
    • Hurwitz, H.I.1    Yi, J.2    Ince, W.3
  • 37
    • 59749091477 scopus 로고    scopus 로고
    • Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
    • Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360:563-572.
    • (2009) N Engl J Med , vol.360 , pp. 563-572
    • Tol, J.1    Koopman, M.2    Cats, A.3
  • 38
    • 77956191440 scopus 로고    scopus 로고
    • Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL trial. 2010 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, FL, USA, Jan 22-24: 281 (abstr).
    • Van Cutsem E I, Lang G, Folprecht et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL trial. 2010 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, FL, USA, Jan 22-24, 2010: 281 (abstr).
    • (2010)
    • Van Cutsem, E.I.1    Lang, G.2    Folprecht3
  • 39
    • 39149097520 scopus 로고    scopus 로고
    • Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer
    • Masi G, Vasile E, Loupakis F, et al. Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2008, 7:7-14.
    • (2008) Clin Colorectal Cancer , vol.7 , pp. 7-14
    • Masi, G.1    Vasile, E.2    Loupakis, F.3
  • 40
    • 77950390607 scopus 로고    scopus 로고
    • Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients
    • Loupakis F, Bocci G, Pasqualetti G, et al. Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients. Curr Cancer Drug Targets 2010, 10:37-45.
    • (2010) Curr Cancer Drug Targets , vol.10 , pp. 37-45
    • Loupakis, F.1    Bocci, G.2    Pasqualetti, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.